WALLAC OY

Their core work

Wallac Oy is a Finnish subsidiary of PerkinElmer, a global diagnostics and life sciences corporation headquartered in Turku, specializing in laboratory instruments for newborn screening, genetic testing, and clinical diagnostics. Their flagship technologies include time-resolved fluorescence platforms (DELFIA) and automated reader systems widely deployed in national newborn screening programs across Europe and beyond. In the SCREEN4CARE project they contribute their instrumentation and screening expertise to accelerating rare disease diagnosis through expanded newborn genetic screening combined with digital data platforms and machine-learning phenotypic tools. They sit at the intersection of wet-lab instrumentation and digital health infrastructure, making them a rare industrial actor within rare disease research consortia.

What they specialise in

How they've shifted over time

In their first H2020 appearance, Wallac participated as a third party in ABWET (2015–2018), an MSCA doctoral training network on biological waste-to-energy — a peripheral role almost certainly tied to providing laboratory equipment access or hosting doctoral researchers, not a sign of genuine energy expertise. By 2021, their focus shifted decisively to their core business domain: rare disease diagnostics, expanded newborn screening, and digital health data infrastructure through SCREEN4CARE. The trajectory reveals a maturation from incidental training-network presence to purposeful industrial partnership in a major RIA project that directly targets commercial deployment of their screening platforms.

Wallac is deepening its role as an industrial reference partner for large-scale genetic screening programs, and their growing engagement with digital platforms and machine learning suggests they are positioning their instruments within broader health data ecosystems — moving from selling hardware toward enabling end-to-end screening infrastructure.

How they like to work

Wallac consistently joins consortia as a participant or third party rather than leading, reflecting the typical posture of a large industrial subsidiary providing specialized instrumentation and commercial expertise to academically-led projects. Their 60 unique consortium partners across 19 countries — from just two projects — signals involvement in broad, pan-European alliances rather than tight bilateral collaborations. As part of the PerkinElmer group, they bring recognized brand credibility and production-scale capability that makes them attractive as an industrial anchor for research consortia seeking a path from laboratory to clinical deployment.

Despite only two H2020 projects, Wallac has reached 60 unique consortium partners across 19 countries, reflecting participation in large multi-partner research alliances typical of health RIA and MSCA networks. Their network is predominantly European, consistent with their focus on EU public health programs and continental screening infrastructure.

What sets them apart

Wallac Oy is one of the few established commercial diagnostic instrument manufacturers directly embedded in EU rare disease research consortia — a position that bridges research-stage genomic screening and real-world clinical deployment at national program scale. As part of PerkinElmer they offer access to commercially validated, regulatory-compliant screening platforms that academic partners cannot replicate internally. For a consortium needing an industrial partner who can translate research outputs into deployable tools for healthcare systems, Wallac provides a direct path from proof-of-concept to national screening program implementation.

Highlights from their portfolio

• SCREEN4CARE
  A 2021–2026 RIA project combining newborn genetic screening with digital health platforms and machine learning to drastically reduce rare disease diagnosis time — directly aligned with Wallac's commercial product lines and placing them at the forefront of next-generation screening infrastructure.
• ABWET
  An MSCA-ITN doctoral training network on biological waste-to-energy (2015–2018) where Wallac appeared as a third party, revealing their early use of EU frameworks for researcher training even outside their primary diagnostics domain.